- Home
- A-Z Publications
- Current Proteomics
- Fast Track Listing
Current Proteomics - Online First
Description text for Online First listing goes here...
-
-
Comparative Clinical, Proteomic, and Serologic Evaluation in Non-Hospitalized COVID-19 Patients and Healthy Individuals
Authors: Solmaz Alihosseini, Hakimeh Zali, Ahmad Majd, Monireh Movahedi and Hamed AbdollahiAvailable online: 14 October 2024More LessIntroductionThe COVID-19 pandemic, caused by the SARS-CoV-2 virus, has had a significant global impact since its declaration as a public health emergency in January 2020. Symptoms of COVID-19 can range from mild to severe, including fever, cough, fatigue, and shortness of breath. This study aimed to investigate the clinical symptoms and proteomic differences between non-hospitalized COVID-19 patients and healthy individuals.
MethodClinical data of 6231 COVID-19 patients of different age groups and sexes were collected and analyzed. Proteins were separated by SDS-PAGE and identified by MALDI-TOF. 900 serum samples were collected, with 100 samples per patient group and one healthy control group.
ResultIn the control group of healthy individuals, five proteins (HAPTO, IGKC, FUT10, CO3, SESQ2) were expressed with a score of 1+, serving as a reference for the other groups. Group 9, consisting of individuals who had recovered (IgG positive), showed negative results for all five proteins due to anti-IgG antibody production in memory cells. The significant differences in protein expression compared to the control group indicated up-regulation and down-regulation of these proteins. Positive PCR or IgG and IgM results led to notable differences in protein expression across all studied groups.
ConclusionThe altered protein expression in infected individuals compared to healthy controls may suggest the potential for these proteins to serve as biomarkers for disease diagnosis and prognosis.
-
-
-
Determination of FGFR1 Functions in Cytarabine Treatment of Acute Myeloid Leukemia Through Bioinformatics Analysis
Authors: Sema Misir, Serap Ozer Yaman, Okan Aykac, Osman Akidan, Irem Bozbey Merde and Ceylan HepokurAvailable online: 09 October 2024More LessAimAmong the most prevalent subtypes of acute leukemia is acute myeloid leukemia (LAML). Consequently, it is essential to understand the molecular causes of LAML and find its predictive and diagnostic biomarkers. The aim of this study is to determine the molecular functions of fibroblast growth factor receptor 1(FGFR1) involved in LAML pathogenesis and its potential therapeutic effect for AML treatment.
MethodsThe molecular docking interaction of the Cytarabine with its target FGFR1 was examined. The Gene Expression Profiling Interactive Analysis, version 2 (GEPIA2), and UALCAN tools database were used to obtain the LAML gene expression datasets. Gene functional annotation was performed to investigate the DEGs' possible role. Using the Interactive Gene database retrieval tool (STRING) and a few chosen hub modules from the GeneMANIA database, the protein-protein interaction (PPI) network were constructed. A survival analysis was performed on the effects of hub genes on the overall survival of LAML patients.
ResultsAs a result of docking, a strong interaction was observed between cytarabine and FGFR1. It has been discovered that cytarabine can reverse FGFR1 expression. The survival study results showed an association between the prognosis of AML patients and one of the central genes, FGFR1.
ConclusionThe expression profile and functions of FGFR1 were determined in LAML patients. It has been shown that FGFR1 can be a viable therapeutic target for LAML and a possible biomarker for diagnosis.
-
-
-
In Vitro and In Silico Evaluation of Caffeic and Ferulic Acids Involvement in the Translocation of Glucose Transporter 4
Authors: Najlaa Bassalat, Shahd Abu Naim, Waseim Barriah, JArg Labahn, Siba Shanak and Hilal ZaidAvailable online: 08 October 2024More LessBackgroundInsulin is a key hormone in our systems. Upon binding of insulin to its receptors in fat and muscle tissues, tens of proteins in the insulin signaling pathway are involved in the process of GLUT4 vesicle recruitment to the Plasma Membrane (PM) and the absorption of serum glucose. Deficits in the aforementioned pathway lead to insulin resistance and eventually to Type II Diabetes Mellitus.
ObjectiveWe appreciate the contribution of phytochemicals in the treatment of diabetes. Yet, in vitro and in silico studies are needed to validate the safety and efficacy of the phytochemicals, plus their action mechanisms.
MethodsHerein, we tested two phytochemicals, caffeic acid and ferulic acid in vitro and in silico. We shed light on the insulin signaling proteins as plausible therapeutic targets using in silico studies, via AutoDock and SwissADME.
ResultsResults obtained in vitro indicate that Caffeic Acid (CA) increased GLUT4 translocation at 125µM by 31% in the absence of insulin, and 24.5% in presence of insulin, when compared to the control. Ferulic Acid (FA) was less potent as an enhancer of GLUT4 translocation. Best docking results were found for the binding of the phytochemicals CA and FA to PDK1, AKT, IRS1 and PTEN proteins of the insulin signaling, with comparable results.
ConclusionThese findings indicate that CA and FA possess a limited anti-diabetic potency by increasing GLUT4 trafficking to the PM in skeletal muscles. These results suggest that these compounds are candidates for further investigation in pre-clinical and clinical stages of drug discovery.
-
-
-
Identifying Prostaglandin D2 Synthase in Urine: A Potential Biomarker for Bladder Cancer
Authors: Lia-Beng Tan, Yu-Chang Tyan, Jen-Yi Hsu, Kun-Hung Hsen, Pao-Chi Liao and How-Ran GuoAvailable online: 03 October 2024More LessIntroductionProteins present in body fluids harbor the potential to act as markers for both diagnosing diseases and exploring their underlying mechanisms. As urine can be easily obtained non-invasively, analyzing its proteins is an ideal approach to identifying biomarkers for bladder cancer. This study aimed to identify proteins in urine that could serve as biomarkers for bladder cancer.
MethodUrine samples were collected from patients with primary transitional cell carcinoma of the bladder and their age and sex-matched healthy individuals. The protein pellet underwent resolubilization and trypsin digestion to facilitate analysis using reverse phase nano-high performance liquid chromatography/electrospray ionization tandem mass spectrometry.
ResultIn samples obtained from 16 patients and 8 controls, 3192 peptides were identified, corresponding to 934 unique proteins, of which 60 were identified with higher confidence levels. Among them, Transferrin and Prostaglandin D2 Synthase (PTGDS) were found as potential markers of bladder cancer. In particular, the absence of PTGDS has a specificity of 100% and a sensitivity of 81%.
ConclusionThis study, which used proteomic approaches, identified PTGDS in urine as a potential biomarker of bladder cancer.
-
-
-
Identification of Novel Biomarkers for Post-Kasai Portoenterostomy in Biliary Atresia through Shotgun Proteomics Analysis
Available online: 13 September 2024More LessIntroductionBiliary Atresia (BA) causes neonatal cholestasis jaundice. The primary therapeutic treatment for BA is the Kasai portoenterostomy. Current diagnostic approaches for BA are imprecise and time-consuming, making early diagnosis crucial for successful treatment outcomes.
ObjectiveThis study aims to analyze proteins from Peripheral Blood Mononuclear Cells (PBMCs) obtained from children with BA compared with healthy children
Methods and Study DesignWe employed a large-scale, total shotgun quantitative serum proteomics approach to analyze the protein from PBMC samples from a discovery cohort. This approach allowed for the simultaneous identification and quantification of multiple proteins, enabling the detection of disease-specific protein expression patterns. The study is proteomic-based study.
ResultsWe identified 24 proteins, by Liquid Chromatography-Mass Spectrometry (LC-MS) analysis that exhibited high discriminatory power for five subjects with BA post-Kasai operation compared to ten healthy controls. ATP2A3, LIN28B, SLC25A3, ITGB3, COX5A, and HLA-B identified proteins of upregulation were predicted to associate with BA post-Kasai operation.
DiscussionOur findings highlight the utility of proteomic techniques in BA research. The identified proteomic markers offer promise for improving BA diagnostic accuracy and timeliness, leading to enhanced treatment outcomes for affected children.
ConclusionProteomic analysis revealed a set of potential biomarkers for early and accurate diagnosis of biliary atresia. These biomarkers hold significant clinical value and have the potential to transform the management of biliary atresia by facilitating timely intervention and improving patient outcomes.
-